Which has higher earnings and valuation, ENTX or CTXR?

Entera Bio is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Entera Bio N/A N/A -$11.44M -$0.27 N/A Citius Pharmaceuticals N/A N/A -$37.43M -$2.13 N/A

Is ENTX or CTXR more profitable?

Citius Pharmaceuticals' return on equity of -61.09% beat Entera Bio's return on equity. Company Net Margins Return on Equity Return on Assets Entera Bio N/A -83.31% -70.83% Citius Pharmaceuticals N/A -61.09% -35.36%

Which has stronger earnings & valuation, FLNA or CTXR?

Cassava Sciences is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cassava Sciences N/A N/A -$90.97M -$1.61 N/A Citius Pharmaceuticals N/A N/A -$37.43M -$2.13 N/A

Is FLNA or CTXR more profitable?

Cassava Sciences' return on equity of -53.90% beat Citius Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Cassava Sciences N/A -53.90% -34.20% Citius Pharmaceuticals N/A -61.09% -35.36%

Which has stronger earnings & valuation, CNTX or CTXR?

Context Therapeutics is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Context Therapeutics N/A N/A -$36.12M -$0.42 N/A Citius Pharmaceuticals N/A N/A -$37.43M -$2.13 N/A

Is CNTX or CTXR more profitable?

Context Therapeutics' return on equity of -59.95% beat Citius Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Context Therapeutics N/A -59.95% -54.78% Citius Pharmaceuticals N/A -61.09% -35.36%

Is CTXR or TLPH more profitable?

Citius Pharmaceuticals' return on equity of -61.09% beat Talphera's return on equity. Company Net Margins Return on Equity Return on Assets Citius Pharmaceuticals N/A -61.09% -35.36% Talphera N/A -92.98% -53.22%

Citius Pharmaceuticals (CTXR) Competitors

$0.54 0.00 (0.00%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$0.55 +0.01 (+1.85%)

As of 07:33 AM Eastern

Compare

CTXR vs. ENTX, FLNA, CNTX, XLO, and TLPH

Should you buy Citius Pharmaceuticals stock or one of its competitors? MarketBeat compares Citius Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Citius Pharmaceuticals include Entera Bio (ENTX), Cassava Sciences (FLNA), Context Therapeutics (CNTX), Xilio Therapeutics (XLO), and Talphera (TLPH). These companies are all part of the "pharmaceutical products" industry.

How does Citius Pharmaceuticals compare to Entera Bio?

Entera Bio (NASDAQ:ENTX) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Entera Bio is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	N/A	N/A	-$11.44M	-$0.27	N/A
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.13	N/A

14.1% of Entera Bio shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 10.6% of Entera Bio shares are held by company insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Entera Bio currently has a consensus price target of $9.00, indicating a potential upside of 445.12%. Citius Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 825.93%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Citius Pharmaceuticals is more favorable than Entera Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Entera Bio has a beta of 1.56, suggesting that its share price is 56% more volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

In the previous week, Entera Bio had 5 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 6 mentions for Entera Bio and 1 mentions for Citius Pharmaceuticals. Citius Pharmaceuticals' average media sentiment score of 1.87 beat Entera Bio's score of 0.72 indicating that Citius Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Entera Bio	Positive
Citius Pharmaceuticals	Very Positive

Citius Pharmaceuticals' return on equity of -61.09% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-83.31%	-70.83%
Citius Pharmaceuticals	N/A	-61.09%	-35.36%

Summary

Citius Pharmaceuticals beats Entera Bio on 8 of the 13 factors compared between the two stocks.

How does Citius Pharmaceuticals compare to Cassava Sciences?

Cassava Sciences (NASDAQ:FLNA) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

38.1% of Cassava Sciences shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 4.6% of Cassava Sciences shares are held by insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Cassava Sciences and Cassava Sciences both had 1 articles in the media. Cassava Sciences' average media sentiment score of 1.87 equaled Citius Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Cassava Sciences	Very Positive
Citius Pharmaceuticals	Very Positive

Cassava Sciences' return on equity of -53.90% beat Citius Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-53.90%	-34.20%
Citius Pharmaceuticals	N/A	-61.09%	-35.36%

Cassava Sciences has a beta of -0.72, suggesting that its share price is 172% less volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

Cassava Sciences is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.13	N/A

Cassava Sciences presently has a consensus target price of $5.00, indicating a potential upside of 316.67%. Citius Pharmaceuticals has a consensus target price of $5.00, indicating a potential upside of 825.93%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Citius Pharmaceuticals is more favorable than Cassava Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Citius Pharmaceuticals beats Cassava Sciences on 7 of the 11 factors compared between the two stocks.

How does Citius Pharmaceuticals compare to Context Therapeutics?

Context Therapeutics (NASDAQ:CNTX) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Context Therapeutics is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.42	N/A
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.13	N/A

14.0% of Context Therapeutics shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 4.8% of Context Therapeutics shares are owned by insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Context Therapeutics had 1 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 2 mentions for Context Therapeutics and 1 mentions for Citius Pharmaceuticals. Citius Pharmaceuticals' average media sentiment score of 1.87 beat Context Therapeutics' score of 1.29 indicating that Citius Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Context Therapeutics	Positive
Citius Pharmaceuticals	Very Positive

Context Therapeutics presently has a consensus price target of $6.17, suggesting a potential upside of 963.22%. Citius Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 825.93%. Given Context Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Context Therapeutics is more favorable than Citius Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Context Therapeutics' return on equity of -59.95% beat Citius Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-59.95%	-54.78%
Citius Pharmaceuticals	N/A	-61.09%	-35.36%

Context Therapeutics has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market.

Summary

Context Therapeutics beats Citius Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Citius Pharmaceuticals compare to Xilio Therapeutics?

Citius Pharmaceuticals (NASDAQ:CTXR) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

Citius Pharmaceuticals has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. Citius Pharmaceuticals' return on equity of -61.09% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Pharmaceuticals	N/A	-61.09%	-35.36%
Xilio Therapeutics	-58.52%	-151.42%	-27.61%

Citius Pharmaceuticals has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market.

16.9% of Citius Pharmaceuticals shares are owned by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are owned by institutional investors. 5.0% of Citius Pharmaceuticals shares are owned by insiders. Comparatively, 7.5% of Xilio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Xilio Therapeutics has higher revenue and earnings than Citius Pharmaceuticals. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.13	N/A
Xilio Therapeutics	$43.77M	1.36	-$35.04M	-$3.55	N/A

Citius Pharmaceuticals currently has a consensus price target of $5.00, indicating a potential upside of 825.93%. Xilio Therapeutics has a consensus price target of $28.00, indicating a potential upside of 209.39%. Given Citius Pharmaceuticals' higher probable upside, equities research analysts plainly believe Citius Pharmaceuticals is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Xilio Therapeutics had 1 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 2 mentions for Xilio Therapeutics and 1 mentions for Citius Pharmaceuticals. Xilio Therapeutics' average media sentiment score of 1.89 beat Citius Pharmaceuticals' score of 1.87 indicating that Xilio Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Citius Pharmaceuticals	Very Positive
Xilio Therapeutics	Very Positive

Summary

Xilio Therapeutics beats Citius Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Citius Pharmaceuticals compare to Talphera?

Citius Pharmaceuticals (NASDAQ:CTXR) and Talphera (NASDAQ:TLPH) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, Citius Pharmaceuticals and Citius Pharmaceuticals both had 1 articles in the media. Talphera's average media sentiment score of 1.89 beat Citius Pharmaceuticals' score of 1.87 indicating that Talphera is being referred to more favorably in the news media.

Company	Overall Sentiment
Citius Pharmaceuticals	Very Positive
Talphera	Very Positive

Talphera has higher revenue and earnings than Citius Pharmaceuticals. Talphera is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.13	N/A
Talphera	$30K	1,781.90	-$14.29M	-$0.31	N/A

Citius Pharmaceuticals has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market. Comparatively, Talphera has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

Citius Pharmaceuticals' return on equity of -61.09% beat Talphera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Pharmaceuticals	N/A	-61.09%	-35.36%
Talphera	N/A	-92.98%	-53.22%

Citius Pharmaceuticals presently has a consensus price target of $5.00, suggesting a potential upside of 825.93%. Talphera has a consensus price target of $3.00, suggesting a potential upside of 191.26%. Given Citius Pharmaceuticals' higher probable upside, equities analysts clearly believe Citius Pharmaceuticals is more favorable than Talphera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

16.9% of Citius Pharmaceuticals shares are held by institutional investors. Comparatively, 37.7% of Talphera shares are held by institutional investors. 5.0% of Citius Pharmaceuticals shares are held by insiders. Comparatively, 3.5% of Talphera shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Citius Pharmaceuticals beats Talphera on 6 of the 11 factors compared between the two stocks.

Get Citius Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTXR vs. The Competition

Export

Metric	Citius Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$14.82M	$3.02B	$6.83B	$12.17B
Dividend Yield	N/A	1.88%	2.67%	6.11%
P/E Ratio	-0.25	19.54	25.88	24.17
Price / Sales	N/A	323.79	548.17	99.03
Price / Cash	N/A	56.85	29.09	36.93
Price / Book	0.13	4.21	10.82	6.38
Net Income	-$37.43M	$64.45M	$3.58B	$337.00M
7 Day Performance	-5.16%	1.32%	1.92%	-0.23%
1 Month Performance	-17.54%	-1.07%	-0.24%	-1.40%
1 Year Performance	-64.71%	29.70%	34.40%	27.76%

Citius Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTXR Citius Pharmaceuticals	2.9498 of 5 stars	$0.54 flat	$5.00 +825.9%	-64.7%	$14.82M	N/A	N/A	20
ENTX Entera Bio	2.7383 of 5 stars	$1.48 +22.3%	$9.00 +508.1%	-13.1%	$59.64M	$40K	N/A	20	High Trading Volume
FLNA Cassava Sciences	2.4868 of 5 stars	$1.24 +1.6%	$5.00 +303.2%	-31.4%	$58.94M	N/A	N/A	20	Positive News Gap Down
CNTX Context Therapeutics	3.7164 of 5 stars	$0.63 -0.3%	$6.17 +879.0%	-12.1%	$58.06M	N/A	N/A	7	Positive News Gap Down
XLO Xilio Therapeutics	2.177 of 5 stars	$8.94 +1.7%	$28.00 +213.2%	-4.3%	$57.79M	$43.77M	N/A	70	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTXR) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Citius Pharmaceuticals (CTXR) Competitors

CTXR vs. ENTX, FLNA, CNTX, XLO, and TLPH

How does Citius Pharmaceuticals compare to Entera Bio?

Summary

How does Citius Pharmaceuticals compare to Cassava Sciences?

Summary

How does Citius Pharmaceuticals compare to Context Therapeutics?

Summary

How does Citius Pharmaceuticals compare to Xilio Therapeutics?

Summary

How does Citius Pharmaceuticals compare to Talphera?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTXR vs. The Competition

Citius Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Citius Pharmaceuticals (CTXR) Competitors

CTXR vs. ENTX, FLNA, CNTX, XLO, and TLPH

How does Citius Pharmaceuticals compare to Entera Bio?

Which has higher earnings and valuation, ENTX or CTXR?

Do institutionals and insiders believe in ENTX or CTXR?

Do analysts prefer ENTX or CTXR?

Which has more volatility and risk, ENTX or CTXR?

Does the media refer more to ENTX or CTXR?

Is ENTX or CTXR more profitable?

Summary

How does Citius Pharmaceuticals compare to Cassava Sciences?

Do insiders and institutionals believe in FLNA or CTXR?

Does the media refer more to FLNA or CTXR?

Is FLNA or CTXR more profitable?

Which has more risk & volatility, FLNA or CTXR?

Which has stronger earnings & valuation, FLNA or CTXR?

Do analysts prefer FLNA or CTXR?

Summary

How does Citius Pharmaceuticals compare to Context Therapeutics?

Which has stronger earnings & valuation, CNTX or CTXR?

Do institutionals and insiders hold more shares of CNTX or CTXR?

Does the media refer more to CNTX or CTXR?

Do analysts recommend CNTX or CTXR?

Is CNTX or CTXR more profitable?

Which has more volatility & risk, CNTX or CTXR?

Summary

How does Citius Pharmaceuticals compare to Xilio Therapeutics?

Is CTXR or XLO more profitable?

Which has more risk & volatility, CTXR or XLO?

Do insiders & institutionals have more ownership in CTXR or XLO?

Which has higher earnings and valuation, CTXR or XLO?

Do analysts rate CTXR or XLO?

Does the media prefer CTXR or XLO?

Summary

How does Citius Pharmaceuticals compare to Talphera?

Does the media prefer CTXR or TLPH?

Which has stronger earnings and valuation, CTXR or TLPH?

Which has more volatility & risk, CTXR or TLPH?

Is CTXR or TLPH more profitable?

Do analysts prefer CTXR or TLPH?

Do insiders & institutionals have more ownership in CTXR or TLPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTXR vs. The Competition

Citius Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools